Jiangsu Vcare Selected Among "2024 China’s Top 500 Hidden Unicorn Enterprises"
Published Time:
2024-11-18 18:09
Source:
At the 2024 China Hidden Unicorn 500 Summit, theDevelopment Report on China’s Top 500 Hidden Unicorn Enterprises 2024was released.Jiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) debuted on this list, showcasing its strong technical accumulation and continuous innovation in independent R&D of innovative drugs and full-chain CRO/CDMO services for pharmaceuticals.
Hidden Unicorns—a new concept—represent high-potential enterprises critical to sci-tech cultivation. The report, the fourth of its kind, uses the Global Unicorn 500 database and Hidden Unicorn evaluation criteria (requiring original/disruptive technologies and irreplicable business models). Through AI-augmented analysis, the top 500 Hidden Unicorns in China were selected.
Since its founding, Jiangsu Vcare has focused on innovative drugs and advanced therapies, evolving into a dual-core enterprise (innovative drug R&D + full-chain CRO/CDMO services). It currently has5 clinical-stage Class I innovative drug projectsand10+ preclinical projects, with a pipeline centered on Vicagrel covering cardiovascular, oncology, and autoimmune diseases. Its CRO/CDMO arm serves 300+ global clients, operating the 130-mu (approx. 8.67 hectares) CDMO facility—Hubei Tianshu Pharmaceutical Co., Ltd.in a provincial chemical park—providing integrated services from advanced intermediates to APIs, and from CMC to clinical CRO and registration.
This recognition affirms Jiangsu Vcare’s "hardcore" R&D strength and future potential. The company will implement a "new quality productivity" strategy, advancing its dual-core model (innovative drugs + full-chain CRO/CDMO) to become a top-tier global pharmaceutical group.
Related News
28
2025
/
04
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced the successful enrollment of the first participant in its Phase II clinical trial for VC005 topical gel, a self-developed next-generation highly selective JAK1 inhibitor, for the treatment of mild-to-moderate atopic dermatitis (AD). The trial aims to evaluate the efficacy of VC005 gel in adult patients with mild-to-moderate AD, providing a critical data for dose selection in future clinical studies and further assesses the drug's safety profile.
View Details
11
2025
/
04
Recently, following joint review by Nanjing Jiangbei New Area Sci-Tech Bureau and Nanjing Municipal Science and Technology Bureau, the"Nanjing Key Laboratory for Artificial Intelligence (AI) Drug Design"established byJiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) was approved as a 2025 Nanjing Key Laboratory. This marks authoritative recognition of Jiangsu Vcare’s scientific capabilities, with the Lab having achieved significant progress in drug design and molecular discovery.
View Details
26
2025
/
03
Jiangsu Vcare Launches Phase II Trial for VC005 Topical Gel in Mild-to-Moderate Atopic Dermatitis
On March 26, 2025, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) officially launched the Phase II clinical trial for its self-developed, highly selective JAK1 inhibitor VC005 gel for the topical treatment of mild-to-moderate atopic dermatitis (AD). The completed Phase I clinical study of VC005 gel demonstrated excellent safety and significant efficacy.
View Details
27
2025
/
01
Jiangsu Vcare Honored As: National-Level Specialized, Refined, Unique, and Innovative "Little Giant" Enterprises; Top 100 China Pharma Innovation Seed Enterprises; Jiangsu Listed Sci-Tech Enterprise Cultivation Program; Jiangsu Chemical Innovative Drug Engineering Research Center; Top 500 China Hidden Unicorn Enterprises
View Details
26
2025
/
01
In January 2025, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced that its self-developed next-generation anti-resistant TRK inhibitor VC004 capsule has officially entered the domestic NDA preparation phase, initiating pre-NDA communications with regulatory authorities. Marking this milestone, Jiangsu Vcare has joined the top tier of domestic self-developed drugs targeting this pathway at remarkable speed.
View Details
22
2025
/
01
Jiangsu Vcare Secures Nearly CNY 200 Million in Series C+ Financing
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) closed its Series C+ financing round, raising nearly CNY 200 million. The round was jointly invested by Xinghe Venture Capital, Jinlong Investment, SDIC Capital, and Yangtze River Industry Group. The proceeds will accelerate clinical advancement of Jiangsu Vcare’s innovative drug pipelines, strengthen its integrated CRO/CDMO service ecosystem, enhance independent innovation capabilities, and advance strategic initiatives in synthetic biology and green chemistry. This brings Jiangsu Vcare’s total equity financing to over CNY 1 billion, demonstrating sustained capital market confidence.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
Powerby：www.300.cn nanjing.300.cn